Tag: cell and gene therapy cdmo market growth

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Revenue Outlook: What CAGR Is Expected Through 2030?

The contract development and manufacturing organization (CDMO) sector focused on cell and gene therapies has experienced remarkable expansion lately, projecting a leap from a valuation of $6.92 billion in 2025 to $8.85 billion in 2026, spurred by a compound annual growth rate (CAGR) of 27.8%. This surge during the past period has been fueled by several factors, including a greater reliance on external partners for manufacturing advanced therapies, the constrained internal manufacturing capacities of many organizations, the proliferation of emerging biotechnology firms, a heightened focus on developing treatments for rare diseases, and an escalating demand for highly specialized skills within the industry.

The cell and gene therapy contract development and manufacturing organization (CDMO) market is poised for substantial expansion, anticipating a surge to $21.35 billion by 2030, propelled by a 24.6% compound annual growth rate (CAGR). This projected expansion over the forthcoming years is fueled by several key factors: the increasing commercial viability of gene-modified therapeutic approaches, a heightened need for adaptable manufacturing capabilities, the broadening scope of international CDMO collaborations, escalating investments poured into cell therapy development pipelines, and a growing number of regulatory endorsements for cutting-edge therapies. Within this forecast period, discernible trends include CDMOs broadening their service portfolios to encompass the entire development lifecycle, a greater requirement for manufacturing support at a commercial scale, the increasing utilization of sophisticated gene editing technologies, a pronounced emphasis on expediting development schedules, and a more robust incorporation of regulatory support services.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15753&type=smp

Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Industry Drivers: What Is Driving Revenue Growth?

The increasing incidence of cancer is anticipated to be a significant catalyst for the expansion of the cell and gene therapy contract development and manufacturing organization (CDMO) market. Cancer, a collective term for diseases involving the aberrant proliferation and dissemination of cells within the organism, is on the rise due to demographic shifts towards older age groups, alterations in daily habits, environmental factors, and advancements in diagnostic capabilities. Cell and gene therapy CDMOs play a crucial role in addressing the growing burden of cancer by pioneering the development and production of cutting-edge, individualized therapies that yield superior effectiveness and improved patient prognoses. Illustrating this trend, data from the Australian Institute of Health and Welfare, a governmental body in Australia, indicated that in 2023, an estimated 165,000 individuals in Australia received a new cancer diagnosis, a figure translating to more than 450 daily occurrences, with males accounting for approximately 55% of these diagnoses. Consequently, the escalating rate of cancer diagnoses is a primary driver for the cell and gene therapy CDMO market’s growth.

Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Categorization By Product Type And Application

The cell and gene therapy contract development and manufacturing organization (cdmo) market covered in this report is segmented –

1) By Product Type: Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy

2) By Phase: Phase 1, Phase 2, Phase 3

3) By Indication: Oncology, Infectious Diseases, Neurological Disorders, Rare Diseases, Other Indications

Subsegments:

1) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Gene Therapy, Plasmid DNA-Based Gene Therapy

2) By Gene-Modified Cell Therapy: CAR-T Cell Therapy, TCR-T Cell Therapy, NK Cell Therapy

3) By Cell Therapy: Stem Cell Therapy, Progenitor Cell Therapy, Immune Cell Therapy

#Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Growth Trends: What Is Influencing The Future Outlook?

Leading entities within the cell and gene therapy contract development and manufacturing organization (CDMO) sector are concentrating on broadening their service offerings by incorporating sophisticated technologies like PluriMatrix, aiming to elevate the manufacturability, operational effectiveness, and product integrity of cell-derived goods. PluriMatrix represents a proprietary platform engineered for the high-volume generation of cell-based therapeutics. This pioneering technology enables the three-dimensional expansion of cells at an industrial scale, thereby ensuring substantial output and uniform quality via a process that is automated, entirely regulated, and thoroughly verified. Illustrating this strategic move, Pluri, a biotechnology firm headquartered in Israel, announced in January 2024 the establishment of PluriCDMO, a new operational segment dedicated to providing contract manufacturing services for cell therapies. This newly formed business unit comprises a significant 47,000-square-foot facility operating under good manufacturing practice (GMP) standards for cell therapy production. Pluri’s recently launched division is equipped to deliver comprehensive support spanning from initial preclinical investigations through advanced clinical phases and eventual market entry, encompassing the entire spectrum of process and analytical development, scaling up manufacturing, validation procedures, logistical management, automation integration, and the execution of regulatory-compliant comparability studies, as outlined in a company press release. The division capitalizes on Pluri’s state-of-the-art PluriMatrix technology to deliver advanced manufacturing capabilities for cell therapies.

Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Company Landscape And Strategic Competition

Major companies operating in the cell and gene therapy contract development and manufacturing organization (cdmo) market are Lonza Group, Catalent Inc, Thermo Fisher Scientific Inc, Samsung Biologics Co Ltd, WuXi Biologics, AGC Biologics, FUJIFILM Diosynth Biotechnologies, Oxford BioMedica Plc, Recipharm AB, Almac Group Ltd, KBI Biopharma, Rentschler Biopharma, Avid Bioservices Inc, Charles River Laboratories International Inc, VGXI Inc, Genezen Laboratories Inc, OmniaBio Inc, Pluri Inc, Cell and Gene Therapy Catapult, BioVectra Inc, Porton Advanced Solutions Ltd

Access The Complete Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Report:

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-contract-development-and-manufacturing-organization-cdmo-global-market-report

Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Leading Geography: Which Region Generates The Most Revenue?

North Americawas the largest region in the cell and gene therapy contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Revenue Outlook: What CAGR Is Expected Through 2030?

The contract development and manufacturing organization (CDMO) sector focused on cell and gene therapies has experienced remarkable expansion lately, projecting a leap from a valuation of $6.92 billion in 2025 to $8.85 billion in 2026, spurred by a compound annual growth rate (CAGR) of 27.8%. This surge during the past period has been fueled by several factors, including a greater reliance on external partners for manufacturing advanced therapies, the constrained internal manufacturing capacities of many organizations, the proliferation of emerging biotechnology firms, a heightened focus on developing treatments for rare diseases, and an escalating demand for highly specialized skills within the industry.

The cell and gene therapy contract development and manufacturing organization (CDMO) market is poised for substantial expansion, anticipating a surge to $21.35 billion by 2030, propelled by a 24.6% compound annual growth rate (CAGR). This projected expansion over the forthcoming years is fueled by several key factors: the increasing commercial viability of gene-modified therapeutic approaches, a heightened need for adaptable manufacturing capabilities, the broadening scope of international CDMO collaborations, escalating investments poured into cell therapy development pipelines, and a growing number of regulatory endorsements for cutting-edge therapies. Within this forecast period, discernible trends include CDMOs broadening their service portfolios to encompass the entire development lifecycle, a greater requirement for manufacturing support at a commercial scale, the increasing utilization of sophisticated gene editing technologies, a pronounced emphasis on expediting development schedules, and a more robust incorporation of regulatory support services.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15753&type=smp

Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Industry Drivers: What Is Driving Revenue Growth?

The increasing incidence of cancer is anticipated to be a significant catalyst for the expansion of the cell and gene therapy contract development and manufacturing organization (CDMO) market. Cancer, a collective term for diseases involving the aberrant proliferation and dissemination of cells within the organism, is on the rise due to demographic shifts towards older age groups, alterations in daily habits, environmental factors, and advancements in diagnostic capabilities. Cell and gene therapy CDMOs play a crucial role in addressing the growing burden of cancer by pioneering the development and production of cutting-edge, individualized therapies that yield superior effectiveness and improved patient prognoses. Illustrating this trend, data from the Australian Institute of Health and Welfare, a governmental body in Australia, indicated that in 2023, an estimated 165,000 individuals in Australia received a new cancer diagnosis, a figure translating to more than 450 daily occurrences, with males accounting for approximately 55% of these diagnoses. Consequently, the escalating rate of cancer diagnoses is a primary driver for the cell and gene therapy CDMO market’s growth.

Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Categorization By Product Type And Application

The cell and gene therapy contract development and manufacturing organization (cdmo) market covered in this report is segmented –

1) By Product Type: Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy

2) By Phase: Phase 1, Phase 2, Phase 3

3) By Indication: Oncology, Infectious Diseases, Neurological Disorders, Rare Diseases, Other Indications

Subsegments:

1) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Gene Therapy, Plasmid DNA-Based Gene Therapy

2) By Gene-Modified Cell Therapy: CAR-T Cell Therapy, TCR-T Cell Therapy, NK Cell Therapy

3) By Cell Therapy: Stem Cell Therapy, Progenitor Cell Therapy, Immune Cell Therapy

#Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Growth Trends: What Is Influencing The Future Outlook?

Leading entities within the cell and gene therapy contract development and manufacturing organization (CDMO) sector are concentrating on broadening their service offerings by incorporating sophisticated technologies like PluriMatrix, aiming to elevate the manufacturability, operational effectiveness, and product integrity of cell-derived goods. PluriMatrix represents a proprietary platform engineered for the high-volume generation of cell-based therapeutics. This pioneering technology enables the three-dimensional expansion of cells at an industrial scale, thereby ensuring substantial output and uniform quality via a process that is automated, entirely regulated, and thoroughly verified. Illustrating this strategic move, Pluri, a biotechnology firm headquartered in Israel, announced in January 2024 the establishment of PluriCDMO, a new operational segment dedicated to providing contract manufacturing services for cell therapies. This newly formed business unit comprises a significant 47,000-square-foot facility operating under good manufacturing practice (GMP) standards for cell therapy production. Pluri’s recently launched division is equipped to deliver comprehensive support spanning from initial preclinical investigations through advanced clinical phases and eventual market entry, encompassing the entire spectrum of process and analytical development, scaling up manufacturing, validation procedures, logistical management, automation integration, and the execution of regulatory-compliant comparability studies, as outlined in a company press release. The division capitalizes on Pluri’s state-of-the-art PluriMatrix technology to deliver advanced manufacturing capabilities for cell therapies.

Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Company Landscape And Strategic Competition

Major companies operating in the cell and gene therapy contract development and manufacturing organization (cdmo) market are Lonza Group, Catalent Inc, Thermo Fisher Scientific Inc, Samsung Biologics Co Ltd, WuXi Biologics, AGC Biologics, FUJIFILM Diosynth Biotechnologies, Oxford BioMedica Plc, Recipharm AB, Almac Group Ltd, KBI Biopharma, Rentschler Biopharma, Avid Bioservices Inc, Charles River Laboratories International Inc, VGXI Inc, Genezen Laboratories Inc, OmniaBio Inc, Pluri Inc, Cell and Gene Therapy Catapult, BioVectra Inc, Porton Advanced Solutions Ltd

Access The Complete Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Report:

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-contract-development-and-manufacturing-organization-cdmo-global-market-report

Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Leading Geography: Which Region Generates The Most Revenue?

North Americawas the largest region in the cell and gene therapy contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Revenue Outlook: What CAGR Is Expected Through 2030?

The contract development and manufacturing organization (CDMO) sector focused on cell and gene therapies has experienced remarkable expansion lately, projecting a leap from a valuation of $6.92 billion in 2025 to $8.85 billion in 2026, spurred by a compound annual growth rate (CAGR) of 27.8%. This surge during the past period has been fueled by several factors, including a greater reliance on external partners for manufacturing advanced therapies, the constrained internal manufacturing capacities of many organizations, the proliferation of emerging biotechnology firms, a heightened focus on developing treatments for rare diseases, and an escalating demand for highly specialized skills within the industry.

The cell and gene therapy contract development and manufacturing organization (CDMO) market is poised for substantial expansion, anticipating a surge to $21.35 billion by 2030, propelled by a 24.6% compound annual growth rate (CAGR). This projected expansion over the forthcoming years is fueled by several key factors: the increasing commercial viability of gene-modified therapeutic approaches, a heightened need for adaptable manufacturing capabilities, the broadening scope of international CDMO collaborations, escalating investments poured into cell therapy development pipelines, and a growing number of regulatory endorsements for cutting-edge therapies. Within this forecast period, discernible trends include CDMOs broadening their service portfolios to encompass the entire development lifecycle, a greater requirement for manufacturing support at a commercial scale, the increasing utilization of sophisticated gene editing technologies, a pronounced emphasis on expediting development schedules, and a more robust incorporation of regulatory support services.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15753&type=smp

Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Industry Drivers: What Is Driving Revenue Growth?

The increasing incidence of cancer is anticipated to be a significant catalyst for the expansion of the cell and gene therapy contract development and manufacturing organization (CDMO) market. Cancer, a collective term for diseases involving the aberrant proliferation and dissemination of cells within the organism, is on the rise due to demographic shifts towards older age groups, alterations in daily habits, environmental factors, and advancements in diagnostic capabilities. Cell and gene therapy CDMOs play a crucial role in addressing the growing burden of cancer by pioneering the development and production of cutting-edge, individualized therapies that yield superior effectiveness and improved patient prognoses. Illustrating this trend, data from the Australian Institute of Health and Welfare, a governmental body in Australia, indicated that in 2023, an estimated 165,000 individuals in Australia received a new cancer diagnosis, a figure translating to more than 450 daily occurrences, with males accounting for approximately 55% of these diagnoses. Consequently, the escalating rate of cancer diagnoses is a primary driver for the cell and gene therapy CDMO market’s growth.

Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Categorization By Product Type And Application

The cell and gene therapy contract development and manufacturing organization (cdmo) market covered in this report is segmented –

1) By Product Type: Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy

2) By Phase: Phase 1, Phase 2, Phase 3

3) By Indication: Oncology, Infectious Diseases, Neurological Disorders, Rare Diseases, Other Indications

Subsegments:

1) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Gene Therapy, Plasmid DNA-Based Gene Therapy

2) By Gene-Modified Cell Therapy: CAR-T Cell Therapy, TCR-T Cell Therapy, NK Cell Therapy

3) By Cell Therapy: Stem Cell Therapy, Progenitor Cell Therapy, Immune Cell Therapy

#Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Growth Trends: What Is Influencing The Future Outlook?

Leading entities within the cell and gene therapy contract development and manufacturing organization (CDMO) sector are concentrating on broadening their service offerings by incorporating sophisticated technologies like PluriMatrix, aiming to elevate the manufacturability, operational effectiveness, and product integrity of cell-derived goods. PluriMatrix represents a proprietary platform engineered for the high-volume generation of cell-based therapeutics. This pioneering technology enables the three-dimensional expansion of cells at an industrial scale, thereby ensuring substantial output and uniform quality via a process that is automated, entirely regulated, and thoroughly verified. Illustrating this strategic move, Pluri, a biotechnology firm headquartered in Israel, announced in January 2024 the establishment of PluriCDMO, a new operational segment dedicated to providing contract manufacturing services for cell therapies. This newly formed business unit comprises a significant 47,000-square-foot facility operating under good manufacturing practice (GMP) standards for cell therapy production. Pluri’s recently launched division is equipped to deliver comprehensive support spanning from initial preclinical investigations through advanced clinical phases and eventual market entry, encompassing the entire spectrum of process and analytical development, scaling up manufacturing, validation procedures, logistical management, automation integration, and the execution of regulatory-compliant comparability studies, as outlined in a company press release. The division capitalizes on Pluri’s state-of-the-art PluriMatrix technology to deliver advanced manufacturing capabilities for cell therapies.

Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Company Landscape And Strategic Competition

Major companies operating in the cell and gene therapy contract development and manufacturing organization (cdmo) market are Lonza Group, Catalent Inc, Thermo Fisher Scientific Inc, Samsung Biologics Co Ltd, WuXi Biologics, AGC Biologics, FUJIFILM Diosynth Biotechnologies, Oxford BioMedica Plc, Recipharm AB, Almac Group Ltd, KBI Biopharma, Rentschler Biopharma, Avid Bioservices Inc, Charles River Laboratories International Inc, VGXI Inc, Genezen Laboratories Inc, OmniaBio Inc, Pluri Inc, Cell and Gene Therapy Catapult, BioVectra Inc, Porton Advanced Solutions Ltd

Access The Complete Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Report:

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-contract-development-and-manufacturing-organization-cdmo-global-market-report

Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Leading Geography: Which Region Generates The Most Revenue?

North Americawas the largest region in the cell and gene therapy contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Expected To Change From 2026 To 2030?

The size of the cell and gene therapy contract development and manufacturing organization (cdmo) market has shown exponential growth over the last few years. This market is projected to expand from $6.92 billion in 2025 to $8.85 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 27.8%. Historically, this expansion was driven by factors such as the increasing demand for outsourcing advanced therapy manufacturing, existing limitations in internal development capabilities, the rise of early-stage biotech companies, the broadening of orphan drug development, and an escalating requirement for specialized expertise.

The cell and gene therapy contract development and manufacturing organization (cdmo) market size is anticipated to undergo significant expansion in the coming years. It is projected to reach $21.35 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 24.6%. This projected growth throughout the forecast period stems from the increasing commercialization of gene-modified therapies, a rising requirement for flexible manufacturing capacity, the expansion of global cdmo partnerships, growing investment in cell therapy pipelines, and increasing regulatory approvals for advanced therapies. Prominent trends identified for this period include the broadening of end-to-end cdmo service offerings, a growing demand for commercial-scale manufacturing support, the rising adoption of advanced gene editing platforms, an increasing emphasis on accelerated development timelines, and enhanced integration of regulatory support services.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-contract-development-and-manufacturing-organization-cdmo-global-market-report

Which Important Drivers Are Guiding The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Growth?

The rising incidence of cancer diagnoses is anticipated to drive the future expansion of the cell and gene therapy contract development and manufacturing organization (CDMO) market. Cancer itself encompasses various conditions defined by the uncontrolled proliferation and spread of abnormal cells throughout the body. The increase in cancer cases can be attributed to an aging global populace, evolving lifestyle choices, environmental exposures, and advancements in detection methods. The cell and gene therapy contract development and manufacturing organization (CDMO) plays a role in mitigating cancer prevalence by developing and manufacturing cutting-edge, targeted treatments that improve both their efficacy and patient outcomes. For instance, in July 2024, the Australian Institute of Health and Welfare, an Australia-based government agency, reported that in 2023, an estimated 165,000 Australians were newly diagnosed with cancer, equivalent to over 450 cases each day, and approximately 55% of these diagnoses were among males. Thus, the escalating prevalence of cancer cases is a key factor boosting the growth of the cell and gene therapy contract development and manufacturing organization (CDMO) market.

How Is The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Broken Down By Segment Categories?

The cell and gene therapy contract development and manufacturing organization (cdmo) market covered in this report is segmented –

1) By Product Type: Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy

2) By Phase: Phase 1, Phase 2, Phase 3

3) By Indication: Oncology, Infectious Diseases, Neurological Disorders, Rare Diseases, Other Indications

Subsegments:

1) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Gene Therapy, Plasmid DNA-Based Gene Therapy

2) By Gene-Modified Cell Therapy: CAR-T Cell Therapy, TCR-T Cell Therapy, NK Cell Therapy

3) By Cell Therapy: Stem Cell Therapy, Progenitor Cell Therapy, Immune Cell Therapy

What Trends Are Influencing The Evolution Of The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?

Leading companies in the cell and gene therapy contract development and manufacturing organization (CDMO) market are prioritizing the expansion of their portfolio with advanced solutions, such as PluriMatrix technology, to enhance the scalability, efficiency, and quality of manufacturing cell-based products. PluriMatrix technology is a proprietary system specifically engineered for the large-scale production of cell-based products. This cutting-edge technology facilitates the industrial-scale 3D expansion of cells, ensuring high yields and consistent quality through an automated, fully controlled, and validated process. For instance, in January 2024, Pluri, an Israel-based biotech firm, launched PluriCDMO, a new business division that provides cell therapy manufacturing services as a contract development and manufacturing organization (CDMO). This new division includes a 47,000-square-foot good manufacturing practice (GMP) cell therapy production facility. As detailed in a company announcement, Pluri’s newly established division offers comprehensive services from early preclinical stages to late-stage clinical trials and commercialization, covering process and analytical development, scale-up, validation, logistics, automation, and regulatory-approved comparability studies. It leverages the company’s advanced PluriMatrix technology to deliver state-of-the-art cell therapy manufacturing services.

Which Players Are Present In The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Space?

Major companies operating in the cell and gene therapy contract development and manufacturing organization (cdmo) market are Lonza Group, Catalent Inc, Thermo Fisher Scientific Inc, Samsung Biologics Co Ltd, WuXi Biologics, AGC Biologics, FUJIFILM Diosynth Biotechnologies, Oxford BioMedica Plc, Recipharm AB, Almac Group Ltd, KBI Biopharma, Rentschler Biopharma, Avid Bioservices Inc, Charles River Laboratories International Inc, VGXI Inc, Genezen Laboratories Inc, OmniaBio Inc, Pluri Inc, Cell and Gene Therapy Catapult, BioVectra Inc, Porton Advanced Solutions Ltd

Get The Full Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Report:

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-contract-development-and-manufacturing-organization-cdmo-global-market-report

Which Region Is The Leading Market For The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?

North America was the largest region in the cell and gene therapy contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-contract-development-and-manufacturing-organization-cdmo-global-market-report

Browse Through More Reports Similar to the Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market 2026, By The Business Research Company

Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization Cdmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/advanced-therapy-medicinal-products-contract-development-and-manufacturing-organization-cdmo-global-market-report

Cell And Gene Therapy Manufacturing Services Market 2026

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-manufacturing-services-market

Cell And Gene Therapy Supply Chain Or Logistics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-supply-chain-or-logistics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Between 2026 And 2030?

The cell and gene therapy contract development and manufacturing organization (cdmo) market has seen substantial growth over recent years. It is forecast to increase from $6.92 billion in 2025 to $8.85 billion in 2026, achieving a compound annual growth rate (CAGR) of 27.8%. This past expansion is primarily due to the rising trend of outsourcing advanced therapy manufacturing, insufficient internal development capacities, the emergence of early-stage biotech companies, the broadening scope of orphan drug development, and a growing requirement for specialized expertise.

The cell and gene therapy contract development and manufacturing organization (cdmo) market size is anticipated to undergo significant growth in the upcoming years. It is predicted to expand to $21.35 billion in 2030, achieving a compound annual growth rate (CAGR) of 24.6%. This projected growth can be attributed to the increasing commercialization of gene-modified therapies, a rising demand for flexible manufacturing capacity, the expansion of global cdmo partnerships, growing investment within cell therapy pipelines, and an increase in regulatory approvals for advanced therapies. Notable trends during this forecast period include the broadening of end-to-end cdmo service offerings, an increasing need for commercial-scale manufacturing support, the rising adoption of advanced gene editing platforms, a stronger focus on accelerated development timelines, and enhanced integration of regulatory support services.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15753&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?

An increasing incidence of cancer is anticipated to fuel the expansion of the cell and gene therapy contract development and manufacturing organization (CDMO) market moving ahead. This medical condition is defined by the unrestrained proliferation and dissemination of abnormal cells within the body. The escalating frequency of cancer cases is attributed to factors like an aging populace, evolving lifestyle choices, environmental exposures, and enhanced diagnostic capabilities. The cell and gene therapy contract development and manufacturing organization (CDMO) assists in mitigating cancer prevalence by developing and producing innovative, targeted treatments that boost efficacy and improve patient outcomes. For instance, in July 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that an estimated 165,000 Australians were newly diagnosed with cancer in 2023, which corresponds to over 450 cases each day, with males comprising approximately 55% of these diagnoses. Consequently, the rising occurrence of cancer cases propels the growth of the cell and gene therapy contract development and manufacturing organization (CDMO) market.

Which Market Segments Are Examined In The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Study?

The cell and gene therapy contract development and manufacturing organization (cdmo) market covered in this report is segmented –

1) By Product Type: Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy

2) By Phase: Phase 1, Phase 2, Phase 3

3) By Indication: Oncology, Infectious Diseases, Neurological Disorders, Rare Diseases, Other Indications

Subsegments:

1) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Gene Therapy, Plasmid DNA-Based Gene Therapy

2) By Gene-Modified Cell Therapy: CAR-T Cell Therapy, TCR-T Cell Therapy, NK Cell Therapy

3) By Cell Therapy: Stem Cell Therapy, Progenitor Cell Therapy, Immune Cell Therapy

Which Trends Are Impacting The Growth Of The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?

Major companies operating within the cell and gene therapy contract development and manufacturing organization (CDMO) market are dedicated to enhancing their service portfolios with sophisticated solutions, such as PluriMatrix technology, to boost the scalability, efficiency, and quality of cell-based product manufacturing. PluriMatrix technology is a proprietary system specifically designed for the large-scale production of cell-based products. This advanced technology enables the 3D expansion of cells at an industrial scale, ensuring high yield and consistent quality through an automated, fully controlled, and validated process. For instance, in January 2024, Pluri, an Israel-based biotech company, launched PluriCDMO, a new business division offering cell therapy manufacturing services as a contract development and manufacturing organization (CDMO). This new division includes a 47,000-square-foot good manufacturing practice (GMP) cell therapy production facility. Pluri’s newly established division provides comprehensive services from early preclinical stages to late-stage clinical trials and commercialization, encompassing process and analytical development, scale-up, validation, logistics, automation, and regulatory-approved comparability studies, as detailed in a company announcement. It leverages the company’s cutting-edge PluriMatrix technology to deliver advanced cell therapy manufacturing services.

Who Are The Primary Competitors In The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?

Major companies operating in the cell and gene therapy contract development and manufacturing organization (cdmo) market are Lonza Group, Catalent Inc, Thermo Fisher Scientific Inc, Samsung Biologics Co Ltd, WuXi Biologics, AGC Biologics, FUJIFILM Diosynth Biotechnologies, Oxford BioMedica Plc, Recipharm AB, Almac Group Ltd, KBI Biopharma, Rentschler Biopharma, Avid Bioservices Inc, Charles River Laboratories International Inc, VGXI Inc, Genezen Laboratories Inc, OmniaBio Inc, Pluri Inc, Cell and Gene Therapy Catapult, BioVectra Inc, Porton Advanced Solutions Ltd

Read the full cell and gene therapy contract development and manufacturing organization (cdmo) market report here:

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-contract-development-and-manufacturing-organization-cdmo-global-market-report

What Are The Leading Geographic Regions In The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?

North America was the largest region in the cell and gene therapy contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15753&type=smp

Browse Through More Reports Similar to the Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market 2026, By The Business Research Company

Cell And Gene Therapy Manufacturing Services Market

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-manufacturing-services-market

Genes Therapy Global Market Report

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Cell And Gene Therapy Supply Chain Or Logistics Global Market Report

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-supply-chain-or-logistics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Between 2026 And 2030?

The cell and gene therapy contract development and manufacturing organization (cdmo) market has seen substantial growth over recent years. It is forecast to increase from $6.92 billion in 2025 to $8.85 billion in 2026, achieving a compound annual growth rate (CAGR) of 27.8%. This past expansion is primarily due to the rising trend of outsourcing advanced therapy manufacturing, insufficient internal development capacities, the emergence of early-stage biotech companies, the broadening scope of orphan drug development, and a growing requirement for specialized expertise.

The cell and gene therapy contract development and manufacturing organization (cdmo) market size is anticipated to undergo significant growth in the upcoming years. It is predicted to expand to $21.35 billion in 2030, achieving a compound annual growth rate (CAGR) of 24.6%. This projected growth can be attributed to the increasing commercialization of gene-modified therapies, a rising demand for flexible manufacturing capacity, the expansion of global cdmo partnerships, growing investment within cell therapy pipelines, and an increase in regulatory approvals for advanced therapies. Notable trends during this forecast period include the broadening of end-to-end cdmo service offerings, an increasing need for commercial-scale manufacturing support, the rising adoption of advanced gene editing platforms, a stronger focus on accelerated development timelines, and enhanced integration of regulatory support services.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15753&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?

An increasing incidence of cancer is anticipated to fuel the expansion of the cell and gene therapy contract development and manufacturing organization (CDMO) market moving ahead. This medical condition is defined by the unrestrained proliferation and dissemination of abnormal cells within the body. The escalating frequency of cancer cases is attributed to factors like an aging populace, evolving lifestyle choices, environmental exposures, and enhanced diagnostic capabilities. The cell and gene therapy contract development and manufacturing organization (CDMO) assists in mitigating cancer prevalence by developing and producing innovative, targeted treatments that boost efficacy and improve patient outcomes. For instance, in July 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that an estimated 165,000 Australians were newly diagnosed with cancer in 2023, which corresponds to over 450 cases each day, with males comprising approximately 55% of these diagnoses. Consequently, the rising occurrence of cancer cases propels the growth of the cell and gene therapy contract development and manufacturing organization (CDMO) market.

Which Market Segments Are Examined In The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Study?

The cell and gene therapy contract development and manufacturing organization (cdmo) market covered in this report is segmented –

1) By Product Type: Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy

2) By Phase: Phase 1, Phase 2, Phase 3

3) By Indication: Oncology, Infectious Diseases, Neurological Disorders, Rare Diseases, Other Indications

Subsegments:

1) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Gene Therapy, Plasmid DNA-Based Gene Therapy

2) By Gene-Modified Cell Therapy: CAR-T Cell Therapy, TCR-T Cell Therapy, NK Cell Therapy

3) By Cell Therapy: Stem Cell Therapy, Progenitor Cell Therapy, Immune Cell Therapy

Which Trends Are Impacting The Growth Of The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?

Major companies operating within the cell and gene therapy contract development and manufacturing organization (CDMO) market are dedicated to enhancing their service portfolios with sophisticated solutions, such as PluriMatrix technology, to boost the scalability, efficiency, and quality of cell-based product manufacturing. PluriMatrix technology is a proprietary system specifically designed for the large-scale production of cell-based products. This advanced technology enables the 3D expansion of cells at an industrial scale, ensuring high yield and consistent quality through an automated, fully controlled, and validated process. For instance, in January 2024, Pluri, an Israel-based biotech company, launched PluriCDMO, a new business division offering cell therapy manufacturing services as a contract development and manufacturing organization (CDMO). This new division includes a 47,000-square-foot good manufacturing practice (GMP) cell therapy production facility. Pluri’s newly established division provides comprehensive services from early preclinical stages to late-stage clinical trials and commercialization, encompassing process and analytical development, scale-up, validation, logistics, automation, and regulatory-approved comparability studies, as detailed in a company announcement. It leverages the company’s cutting-edge PluriMatrix technology to deliver advanced cell therapy manufacturing services.

Who Are The Primary Competitors In The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?

Major companies operating in the cell and gene therapy contract development and manufacturing organization (cdmo) market are Lonza Group, Catalent Inc, Thermo Fisher Scientific Inc, Samsung Biologics Co Ltd, WuXi Biologics, AGC Biologics, FUJIFILM Diosynth Biotechnologies, Oxford BioMedica Plc, Recipharm AB, Almac Group Ltd, KBI Biopharma, Rentschler Biopharma, Avid Bioservices Inc, Charles River Laboratories International Inc, VGXI Inc, Genezen Laboratories Inc, OmniaBio Inc, Pluri Inc, Cell and Gene Therapy Catapult, BioVectra Inc, Porton Advanced Solutions Ltd

Read the full cell and gene therapy contract development and manufacturing organization (cdmo) market report here:

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-contract-development-and-manufacturing-organization-cdmo-global-market-report

What Are The Leading Geographic Regions In The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?

North America was the largest region in the cell and gene therapy contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15753&type=smp

Browse Through More Reports Similar to the Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market 2026, By The Business Research Company

Cell And Gene Therapy Manufacturing Services Market

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-manufacturing-services-market

Genes Therapy Global Market Report

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Cell And Gene Therapy Supply Chain Or Logistics Global Market Report

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-supply-chain-or-logistics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Between 2026 And 2030?

The cell and gene therapy contract development and manufacturing organization (cdmo) market has seen substantial growth over recent years. It is forecast to increase from $6.92 billion in 2025 to $8.85 billion in 2026, achieving a compound annual growth rate (CAGR) of 27.8%. This past expansion is primarily due to the rising trend of outsourcing advanced therapy manufacturing, insufficient internal development capacities, the emergence of early-stage biotech companies, the broadening scope of orphan drug development, and a growing requirement for specialized expertise.

The cell and gene therapy contract development and manufacturing organization (cdmo) market size is anticipated to undergo significant growth in the upcoming years. It is predicted to expand to $21.35 billion in 2030, achieving a compound annual growth rate (CAGR) of 24.6%. This projected growth can be attributed to the increasing commercialization of gene-modified therapies, a rising demand for flexible manufacturing capacity, the expansion of global cdmo partnerships, growing investment within cell therapy pipelines, and an increase in regulatory approvals for advanced therapies. Notable trends during this forecast period include the broadening of end-to-end cdmo service offerings, an increasing need for commercial-scale manufacturing support, the rising adoption of advanced gene editing platforms, a stronger focus on accelerated development timelines, and enhanced integration of regulatory support services.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15753&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?

An increasing incidence of cancer is anticipated to fuel the expansion of the cell and gene therapy contract development and manufacturing organization (CDMO) market moving ahead. This medical condition is defined by the unrestrained proliferation and dissemination of abnormal cells within the body. The escalating frequency of cancer cases is attributed to factors like an aging populace, evolving lifestyle choices, environmental exposures, and enhanced diagnostic capabilities. The cell and gene therapy contract development and manufacturing organization (CDMO) assists in mitigating cancer prevalence by developing and producing innovative, targeted treatments that boost efficacy and improve patient outcomes. For instance, in July 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that an estimated 165,000 Australians were newly diagnosed with cancer in 2023, which corresponds to over 450 cases each day, with males comprising approximately 55% of these diagnoses. Consequently, the rising occurrence of cancer cases propels the growth of the cell and gene therapy contract development and manufacturing organization (CDMO) market.

Which Market Segments Are Examined In The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Study?

The cell and gene therapy contract development and manufacturing organization (cdmo) market covered in this report is segmented –

1) By Product Type: Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy

2) By Phase: Phase 1, Phase 2, Phase 3

3) By Indication: Oncology, Infectious Diseases, Neurological Disorders, Rare Diseases, Other Indications

Subsegments:

1) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Gene Therapy, Plasmid DNA-Based Gene Therapy

2) By Gene-Modified Cell Therapy: CAR-T Cell Therapy, TCR-T Cell Therapy, NK Cell Therapy

3) By Cell Therapy: Stem Cell Therapy, Progenitor Cell Therapy, Immune Cell Therapy

Which Trends Are Impacting The Growth Of The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?

Major companies operating within the cell and gene therapy contract development and manufacturing organization (CDMO) market are dedicated to enhancing their service portfolios with sophisticated solutions, such as PluriMatrix technology, to boost the scalability, efficiency, and quality of cell-based product manufacturing. PluriMatrix technology is a proprietary system specifically designed for the large-scale production of cell-based products. This advanced technology enables the 3D expansion of cells at an industrial scale, ensuring high yield and consistent quality through an automated, fully controlled, and validated process. For instance, in January 2024, Pluri, an Israel-based biotech company, launched PluriCDMO, a new business division offering cell therapy manufacturing services as a contract development and manufacturing organization (CDMO). This new division includes a 47,000-square-foot good manufacturing practice (GMP) cell therapy production facility. Pluri’s newly established division provides comprehensive services from early preclinical stages to late-stage clinical trials and commercialization, encompassing process and analytical development, scale-up, validation, logistics, automation, and regulatory-approved comparability studies, as detailed in a company announcement. It leverages the company’s cutting-edge PluriMatrix technology to deliver advanced cell therapy manufacturing services.

Who Are The Primary Competitors In The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?

Major companies operating in the cell and gene therapy contract development and manufacturing organization (cdmo) market are Lonza Group, Catalent Inc, Thermo Fisher Scientific Inc, Samsung Biologics Co Ltd, WuXi Biologics, AGC Biologics, FUJIFILM Diosynth Biotechnologies, Oxford BioMedica Plc, Recipharm AB, Almac Group Ltd, KBI Biopharma, Rentschler Biopharma, Avid Bioservices Inc, Charles River Laboratories International Inc, VGXI Inc, Genezen Laboratories Inc, OmniaBio Inc, Pluri Inc, Cell and Gene Therapy Catapult, BioVectra Inc, Porton Advanced Solutions Ltd

Read the full cell and gene therapy contract development and manufacturing organization (cdmo) market report here:

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-contract-development-and-manufacturing-organization-cdmo-global-market-report

What Are The Leading Geographic Regions In The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?

North America was the largest region in the cell and gene therapy contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15753&type=smp

Browse Through More Reports Similar to the Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market 2026, By The Business Research Company

Cell And Gene Therapy Manufacturing Services Market

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-manufacturing-services-market

Genes Therapy Global Market Report

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Cell And Gene Therapy Supply Chain Or Logistics Global Market Report

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-supply-chain-or-logistics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model